Summary
The provided statements are largely general manufacturing/mechanism/classification claims that are not clearly addressed by the supplied FARXIGA prescribing information excerpts. Additionally, the label-evaluation context is insufficient to verify whether these non-labeled claims align with the FDA-approved prescribing information.
Category Scores
Accurate Statements
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Supported by FARXIGA Mechanism of Action (12.1): dapagliflozin is an inhibitor of SGLT2.
Unsupported Statements
Dapagliflozin API is the active pharmaceutical ingredient used to make medicines containing dapagliflozin.
Not supported or addressed in the supplied FARXIGA prescribing information excerpts.
Dapagliflozin API is the drug substance that manufacturers formulate into finished products.
Not supported or addressed in the supplied FARXIGA prescribing information excerpts.
Dapagliflozin API is used in branded and generic dapagliflozin medicines.
Not supported or addressed in the supplied FARXIGA prescribing information excerpts.
Dapagliflozin API-based products are marketed for type 2 diabetes.
The label indicates FARXIGA indications include type 2 diabetes mellitus, but the claim is framed generically about API-based products rather than FARXIGA labeling; the supplied excerpts do not directly support the API-based generalization.
Dapagliflozin API-based products may be marketed for other cardiometabolic indications depending on jurisdiction and label.
Not supported by the supplied excerpts as a jurisdiction/label-dependent general statement.
API producers usually need to meet regulatory expectations for identity, purity, and quality for dapagliflozin API.
Not supported or addressed in the supplied FARXIGA prescribing information excerpts.
API producers usually need to meet GMP compliance expectations for dapagliflozin API production.
Not supported or addressed in the supplied FARXIGA prescribing information excerpts.
Finished-dose manufacturers submit product dossiers using the API supplied along with stability and manufacturing data for dapagliflozin products.
Not supported or addressed in the supplied FARXIGA prescribing information excerpts.
Contradictions
Important Omissions
The statements make multiple claims about API manufacturing/regulatory requirements and about generic/API-based marketing without any corresponding verification in the supplied prescribing information. A material, label-aligned focus on FARXIGA-specific dosage, indications, contraindications, and boxed/warning content is missing for the purpose of label alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No dosing, contraindication, warnings, or patient-management claims were made that could directly create immediate patient risk based on the provided excerpts; however, multiple claims are not supported by the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Misaligned
Primary Issue
Most statements are about API manufacturing/regulatory processes and generic/API market usage that are not addressed in the supplied FARXIGA prescribing information excerpts.
Suggested Improvement
Limit assertions to what the FARXIGA label excerpts directly support (e.g., mechanism as an SGLT2 inhibitor; FARXIGA labeled indications/limitations; contraindications; dosing/testing/withholding instructions). Avoid generic API manufacturing/regulatory and jurisdictional marketing assertions unless the label explicitly states them.